{"id":"NCT01301833","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes","officialTitle":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2011-02-23","resultsPosted":"2015-08-28","lastUpdate":"2015-11-18"},"enrollment":462,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"teneligliptin","otherNames":["MP-513"]},{"type":"DRUG","name":"glinide","otherNames":[]},{"type":"DRUG","name":"biguanide","otherNames":[]},{"type":"DRUG","name":"alpha-glucosidase inhibitor","otherNames":[]}],"arms":[{"label":"teneligliptin","type":"EXPERIMENTAL"},{"label":"teneligliptin and glinide","type":"EXPERIMENTAL"},{"label":"teneligliptin and biguanide","type":"EXPERIMENTAL"},{"label":"teneligliptin and alpha-glucosidase inhibitor","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"52 Weeks","effectByArm":[{"arm":"Teneligliptin","deltaMin":14,"sd":null},{"arm":"Teneligliptin and Glinide","deltaMin":3,"sd":null},{"arm":"Teneligliptin and Biguanide","deltaMin":6,"sd":null},{"arm":"Teneligliptin and Alpha-glucosidase Inhibitor","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["25861982"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":212},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Blood urine present","Protein urine present","Blood creatine phosphokinase increased"]}}